These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 6785657)
41. U.S. Preventive Services Task Force is back. Berg AO; Frame PS Am Fam Physician; 1993 Sep; 48(4):573-4. PubMed ID: 8379484 [No Abstract] [Full Text] [Related]
42. Cost-effectiveness estimates for antenatal HIV testing in the Netherlands. Rozenbaum MH; Verweel G; Folkerts DK; Dronkers F; van den Hoek JA; Hartwig NG; de Groot R; Postma MJ Int J STD AIDS; 2008 Oct; 19(10):668-75. PubMed ID: 18824618 [TBL] [Abstract][Full Text] [Related]
43. Screening for Chlamydia trachomatis; the Amsterdam experience. Bleker OP Minerva Ginecol; 2000 Dec; 52(12 Suppl 1):97-9. PubMed ID: 11526697 [No Abstract] [Full Text] [Related]
44. Public health--the other health care system. Gabel HD Md Med J; 1993 Aug; 42(8):722-3. PubMed ID: 8412531 [No Abstract] [Full Text] [Related]
45. Cost-effectiveness of screening for HIV. Thrasher AD; Ford CL; Nearing KA N Engl J Med; 2005 May; 352(20):2137-9; author reply 2137-9. PubMed ID: 15906435 [No Abstract] [Full Text] [Related]
46. Is an ounce of prevention always worth a pound of cure? No: promoting prevention to contain costs is a logical fallacy. Shenkin H West J Med; 2001 Feb; 174(2):85. PubMed ID: 11156899 [No Abstract] [Full Text] [Related]
47. Hygeia or Panacea--which is the better buy? Lawrence RS Internist; 1986 Oct; 27(9):9-10. PubMed ID: 10311718 [No Abstract] [Full Text] [Related]
48. Effects of a cost-sharing exemption on use of preventive services at one large employer. Busch SH; Barry CL; Vegso SJ; Sindelar JL; Cullen MR Health Aff (Millwood); 2006; 25(6):1529-36. PubMed ID: 17102176 [TBL] [Abstract][Full Text] [Related]
49. A comparison of costs of universal versus targeted lead screening for young children. Rolnick SJ; Nordin J; Cherney LM Environ Res; 1999 Jan; 80(1):84-91. PubMed ID: 9931230 [TBL] [Abstract][Full Text] [Related]
50. Valuing prevention: discounting health benefits and costs in New Zealand. Milne R N Z Med J; 2005 May; 118(1214):U1443. PubMed ID: 15886738 [No Abstract] [Full Text] [Related]
52. [Quality adjusted life years in assessment of preventive measures. Should blood donors be tested for HTLV-I/II infections?]. Magnus P; Stigum H; Nord E; Bjørndal A; Samdal HH; Skulberg A; Heier HE Tidsskr Nor Laegeforen; 1996 Apr; 116(10):1229-32. PubMed ID: 8658396 [TBL] [Abstract][Full Text] [Related]
53. How to screen for cervical cancer after HPV16/18 vaccination in The Netherlands. Coupé VM; de Melker HE; Snijders PJ; Meijer CJ; Berkhof J Vaccine; 2009 Aug; 27(37):5111-9. PubMed ID: 19567242 [TBL] [Abstract][Full Text] [Related]
54. Health in the balance. Couser S; Daly G; Grisham J; Rieder B Nurs Outlook; 1986; 34(1):25-7. PubMed ID: 3079901 [No Abstract] [Full Text] [Related]
55. Prevention may be more expensive than cure. Butler JA J R Soc Med; 1993 Jun; 86(6):341-4. PubMed ID: 8315628 [No Abstract] [Full Text] [Related]
56. The economics of prevention. Russell LB Health Policy; 1984; 4(2):85-100. PubMed ID: 10310959 [TBL] [Abstract][Full Text] [Related]
57. [The economic return of cancer prevention]. van Bekkum DW Ned Tijdschr Geneeskd; 1984 Jul; 128(30):1429-31. PubMed ID: 6472509 [No Abstract] [Full Text] [Related]
58. Mediational screening: is the benefit worth the cost? Caldwell RA Am J Community Psychol; 1991 Dec; 19(6):847-51. PubMed ID: 1793092 [TBL] [Abstract][Full Text] [Related]
59. Costs of prevention. Prevention encompasses more than screening. Khaw KT BMJ; 1996 Mar; 312(7032):708. PubMed ID: 8597763 [No Abstract] [Full Text] [Related]
60. Cost-benefit analysis: probabilities and provisos. Rothenberg R Sex Transm Dis; 1983; 10(4):216-8. PubMed ID: 6420910 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]